Aurobindo Pharma arm to acquire 20% additional ownership in Luoxin Aurovitas for Rs 45 crore

Telangana: Aurobindo Pharma has announced that Helix Healthcare B.V., a wholly owned subsidiary of the Company, has entered into a binding agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China, the joint venture partner in Luoxin Aurovitas Pharma (Chengdu) Co. Ltd, China, to acquire 20% additional ownership in Luoxin Aurovitas for USD 5.125 million.

The strategic move aims to expand the manufacturing to economies of scale by adding 2 high Speed Lines and cater market demand.

Under the agreement, the initial acquisition of 20% stake would be acquired within next three months with the right to acquire balance 50% stake by December 2029 at an agreed price of USD 18.86 million subject to certain terms and conditions.

Luoxin Aurovitas was set up as a joint venture company for manufacturing Inhalation products in China on March 25, 2019. It has registered a turnover of USD 2.34 mn during FY 2024-25 and has a net worth of USD 15.29 million as on September 30, 2025.

Read also: Bharat Biotech, Aurobindo and Hetero sign multi crore investment deals in Telangana

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 31 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a R&D set-up.

Read also: Aurobindo Pharma arm Eugia Pharma B.V incorporates wholly owned subsidiary in Chile